CellRight Technologies entered into an agreement granting Arthrex distribution rights to its proprietary BioRinse bone portfolio in Europe, starting with the U.K. The companies entered into their first collaboration in 1Q18, addressing the U.S.
BioRinse sterilization technology is applied to CellRight’s orthobiologic product families of Matrix OI®, MatrixCellect® 100 DBM putty, MatrixCellect® 100 DBM Crunch, ConCelltrate® 100, etc.
CellRight Technologies entered into an agreement granting Arthrex distribution rights to its proprietary BioRinse bone portfolio in Europe, starting with the U.K. The companies entered into their first collaboration in 1Q18, addressing the U.S.
BioRinse sterilization technology is applied to CellRight's orthobiologic product...
CellRight Technologies entered into an agreement granting Arthrex distribution rights to its proprietary BioRinse bone portfolio in Europe, starting with the U.K. The companies entered into their first collaboration in 1Q18, addressing the U.S.
BioRinse sterilization technology is applied to CellRight’s orthobiologic product families of Matrix OI®, MatrixCellect® 100 DBM putty, MatrixCellect® 100 DBM Crunch, ConCelltrate® 100, etc.
Copy to clipboard 
